8608 Background: KRAS-G12C mutations are found in ~12% of mNSCLC. KRAS-G12C inhibitors sotorasib and adagrasib are approved treatments but have never been compared head-to-head. We report the first large, multi-institutional database analysis comparing efficacy and safety of sotarasib vs adagrasib. Methods: Flatiron Health's de-identified electronic health record US database was used to identify patients with KRAS G12C-mutated NSCLC who started treatment 12/2022-10/2025 with either sotorasib or